Professor Mark Sleeman
Mark Sleeman is the Executive Director of the Industry Engagement for the Monash Biomedicine Discovery Institute (BDI). He has a joint appointment in the Department of Physiology and the Department Biochemistry and Molecular Biology and is the Scientific Director of the Monash Antibody Technologies Facility (MATF) and Protein Production Unit (PPU). He maintains an active research laboratory and has an adjunct professorial position at Yale University (since 2008) and the Centre for Comparative Genomics, Murdoch University (since 2013). Prior to returning to Australia, he spent 15 years in New York working with Regeneron Pharmaceuticals Inc., a world leading biopharmaceutical company.
Professor Sleeman is an acknowledged leader in the development of therapeutics for the treatment of metabolic disease, and has published papers in peer-reviewed journals such as Nature Medicine, Nature Genetics, Nature Neuroscience, PNAS, Journal of Clinical Investigation, and Diabetes. He consults for many international pharmaceutical companies and is actively involved in a number of “start up” biotechnology companies with the ambition of advancing and growing this sector in Australia.